Active-Controlled, Parallel-Group Study of SJP-0135 in Patients with Primary Open Angle Glaucoma or Ocular Hypertension

SJP-0135 Phase 3 -A Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel-Group Study in Patients with Primary Open Angle Glaucoma or Ocular Hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230312

Enrollment

140

Registered

2023-09-14

Start date

2023-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary open angle glaucoma or Ocular hypertension

Interventions

Eye administration of SJP-0135 or brimonidine tartrate/ timolol maleate combination ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Aged 18 years or older at the time of Informed Consent (any gender) -Have been diagnosed with primary open angle glaucoma or ocular hypertension -Meet the other protocol-specified inclusion criteria

Exclusion criteria

Exclusion criteria: -Have a history of, or scheduled ocular surgery/laser therapy during the study -Unable to discontinue wearing contact lens during the study -Have active ocular disease other than primary open angle glaucoma or ocular hypertension -Have severe visual field disorders -Have abnormalities that interfere with measurement of intraocular pressure -Have severe systemic illness -Have a history of hypersensitivity or serious adverse reaction to any of the drugs used in the study -Pregnant, lactating, or potentially pregnant -Have judged that it is inappropriate to participate in this study by investigator -Meet the other protocol-specified exclusion criteria

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
Efficacy and safety	—

Contacts

Public Contactdivision Clinical

Senju Pharmaceutical Co., Ltd.

senju-clinicaltrials@senju.co.jp+81-78-777-1018

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026